share_log

Morgan Stanley Downgrades Vigil Neuroscience to Underweight, Lowers Price Target to $4

Morgan Stanley Downgrades Vigil Neuroscience to Underweight, Lowers Price Target to $4

摩根士丹利将Vigil Neuroscience的评级下调至减持,将目标股价下调至4美元
Benzinga ·  2023/12/19 09:31

Morgan Stanley analyst Jeffrey Hung downgrades Vigil Neuroscience (NASDAQ:VIGL) from Equal-Weight to Underweight and lowers the price target from $13 to $4.

摩根士丹利分析师洪杰弗里·洪将Vigil Neuroscience(纳斯达克股票代码:VIGL)的评级从同等权重下调至减持,并将目标股价从13美元下调至4美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发